AI Article Synopsis
- - Efzofitimod is a novel biologic that targets immune responses by modulating neuropilin-2 (NRP2), which is highly expressed in sarcoidosis granulomas.
- - Preclinical tests showed that efzofitimod effectively reduced inflammation caused by P. acnes in an animal model of sarcoidosis.
- - A dose escalation trial in humans indicated that efzofitimod improved quality of life, reduced reliance on glucocorticoids, and stabilized or improved lung function in patients with chronic pulmonary sarcoidosis, leading to a larger Phase 3 trial.
Article Abstract
Efzofitimod is a first-in-class biologic based on a naturally occurring splice variant of histidyl-tRNA synthetase (HARS) that downregulates immune responses via selective modulation of neuropilin-2 (NRP2). Preclinical data found high expression of NRP2 in sarcoidosis granulomas. Treatment with efzofitimod reduced the granulomatous inflammation induced by P. acnes in an animal model of sarcoidosis. A dose escalating trial of efzofitimod in sarcoidosis with chronic symptomatic pulmonary disease found that treatment with efzofitimod was associated with improved quality of life with a trend towards reduced glucocorticoid use and stable to improved pulmonary function. These studies have led to a large Phase 3 trial of efzofitimod in symptomatic pulmonary sarcoidosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099656 | PMC |
| http://dx.doi.org/10.36141/svdld.v40i1.14396 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!